← Back to patent-cliff list
CAS 2012523-61-2
1-[(3R)-1-Benzylpiperidin-3-yl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
Codes: (VII)461018-20-a
Application context (from source-drug indications)
Waldenström macroglobulinaemiaIbrutinibChronic lymphocytic leukaemiaIbrutinibMantle cell lymphomaIbrutinibGraft-versus-host diseaseIbrutinib
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Ibrutinib | Tier A — Act now | 2027 |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
(3S)-1-(tert-Butoxycarbonyl)-3-hydroxypiperidine→(3S)-Piperidin-3-ol--hydrogen chloride (1→(3S)-1-Benzylpiperidin-3-ol→(3S)-1-Benzylpiperidin-3-yl methanesulfonate→2-Propenoic acid→(3S)-Piperidin-3-yl methanesulfonate→3-(4-Phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine→1-[(3R)-1-Benzylpiperidin-3-yl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine→(R)-3-(4-phenoxyphenyl)-1-(piperidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine→2-Propenoyl chloride→1-[(3S)-3-Hydroxypiperidin-1-yl]prop-2-en-1-one→(3S)-1-(Prop-2-enoyl)piperidin-3-yl methanesulfonate
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.